69,300 Shares in Ocular Therapeutix, Inc. $OCUL Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 69,300 shares of the biopharmaceutical company’s stock, valued at approximately $841,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OCUL. KBC Group NV bought a new stake in Ocular Therapeutix during the 4th quarter valued at approximately $78,000. Quarry LP purchased a new stake in Ocular Therapeutix during the 3rd quarter valued at approximately $80,000. Trust Co. of Vermont grew its holdings in Ocular Therapeutix by 24.3% during the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,750 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Ocular Therapeutix by 53.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,353 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 3,626 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in Ocular Therapeutix during the 3rd quarter valued at approximately $126,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Stock Up 3.0%

Shares of NASDAQ OCUL opened at $8.54 on Thursday. The firm’s 50-day moving average price is $8.78 and its 200-day moving average price is $10.24. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -5.85 and a beta of 0.93. Ocular Therapeutix, Inc. has a 12-month low of $6.23 and a 12-month high of $16.44.

Analyst Ratings Changes

A number of equities research analysts have issued reports on OCUL shares. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Monday, April 13th. Chardan Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, February 18th. William Blair reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.